Terms: = Prostate cancer AND PAX5, Q02548, 5079, ENSG00000196092, BSAP
55 results:
1. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.
Amparore D; De Cillis S; Schulman C; Kadner G; Fiori C; Porpiglia F
Minerva Urol Nephrol; 2023 Dec; 75(6):743-751. PubMed ID: 37350585
[TBL] [Abstract] [Full Text] [Related]
2. Spatial patterns of prostate-specific antigen testing in asymptomatic men across Australia: a population-based cohort study, 2017-2018.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Public Health; 2023 Apr; 217():173-180. PubMed ID: 36898290
[TBL] [Abstract] [Full Text] [Related]
3. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant prostate cancer.
Quinn Z; Leiby B; Sonpavde G; Choudhury AD; Sweeney C; Einstein D; Szmulewitz R; Sartor O; Knudsen K; Yang ES; Kelly WK
Clin Cancer Res; 2023 Jan; 29(1):50-59. PubMed ID: 36321991
[TBL] [Abstract] [Full Text] [Related]
4. Modeling oral cancer screening in the United States population.
Cramer JD; Grauer J
Oral Oncol; 2022 Jan; 124():105656. PubMed ID: 34864525
[TBL] [Abstract] [Full Text] [Related]
5. pax5-induced upregulation of LINC01194 exerts oncogenic properties by regulating GOLPH3 expression via miR-486-5p in prostate cancer.
Song HR; Guo XB; Duan Y; Meng HY; Wang ZY
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2528-2541. PubMed ID: 33829439
[TBL] [Abstract] [Full Text] [Related]
6. Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins.
Noé V; Aubets E; Félix AJ; Ciudad CJ
Biochem Pharmacol; 2021 Jul; 189():114371. PubMed ID: 33338475
[TBL] [Abstract] [Full Text] [Related]
7. Contrast enhanced ultrasound (CEUS) with parametric imaging after irreversible electroporation (IRE) of the prostate to assess the success of prostate cancer treatment.
Jung EM; Engel M; Wiggermann P; Schicho A; Lerchbaumer M; Stroszczynski C; Fischer T; Wiesinger I
Clin Hemorheol Microcirc; 2021; 77(3):303-310. PubMed ID: 33337354
[TBL] [Abstract] [Full Text] [Related]
8. Database Mining of Genes of Prognostic Value for the prostate Adenocarcinoma Microenvironment Using the cancer Gene Atlas.
Zhao X; Hu D; Li J; Zhao G; Tang W; Cheng H
Biomed Res Int; 2020; 2020():5019793. PubMed ID: 32509861
[TBL] [Abstract] [Full Text] [Related]
9. pax5-induced upregulation of IDH1-AS1 promotes tumor growth in prostate cancer by regulating ATG5-mediated autophagy.
Zhang N; Li Z; Bai F; Zhang S
Cell Death Dis; 2019 Sep; 10(10):734. PubMed ID: 31570703
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA FOXP4-AS1 is activated by pax5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4.
Wu X; Xiao Y; Zhou Y; Zhou Z; Yan W
Cell Death Dis; 2019 Jun; 10(7):472. PubMed ID: 31209207
[TBL] [Abstract] [Full Text] [Related]
11. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
12. A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan.
Wu CC; Lin CH; Chiang HS; Tang MJ
Int J Equity Health; 2018 Jun; 17(1):79. PubMed ID: 29903010
[TBL] [Abstract] [Full Text] [Related]
13. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract] [Full Text] [Related]
14. Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screening.
Oki R; Ito K; Suzuki R; Fujizuka Y; Arai S; Miyazawa Y; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
Int J Cancer; 2018 Oct; 143(7):1611-1619. PubMed ID: 29696637
[TBL] [Abstract] [Full Text] [Related]
15. Poor Follow-up After Elevated prostate-specific Antigen Tests: A Population-based Cohort Study.
Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
[TBL] [Abstract] [Full Text] [Related]
16. prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancer.
Paoluzzi M; Losa A; Cerboneschi V; Colosimo C; Fontana N; Mangili P; Mignogna M; Nava L; Ravaglia V
Brachytherapy; 2017; 16(5):1000-1006. PubMed ID: 28642046
[TBL] [Abstract] [Full Text] [Related]
17. A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [
Vaishampayan UN; Tehrani OS; Lawhorn-Crews JM; Heilbrun LK; Dobson K; Smith D; Dickow B; Shields AF
Mol Imaging Biol; 2017 Dec; 19(6):810-816. PubMed ID: 28289967
[TBL] [Abstract] [Full Text] [Related]
18. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract] [Full Text] [Related]
19. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
[TBL] [Abstract] [Full Text] [Related]
20. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant prostate cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract] [Full Text] [Related]
[Next]
